Inventiva Stock Falls 5.14% Amid Sectoral Tension

Recent Performance and Market Dynamics

The French biopharmaceutical company's stock ended the session on Monday, October 13, at €3.78, down 5.14% from the previous day when it was trading at €3.99. This correction is part of a pronounced short-term downward trend, with a cumulative drop of 29.21% over the last seven days. However, this movement contrasts with a more favorable medium and long-term trajectory: the price still shows a gain of 36.46% over three months and 130.5% over a year, significantly outperforming the CAC 40, which only increased by 4.7% over the same annual period. Today's trading remained moderate, with a traded capital share of 0.69%, indicating contained activity despite recent volatility. The stock also moved counter to the Parisian index, which ended slightly up by 0.21% at 7,934.26 points.

Factors Influencing the Decline

Several recent events could shed light on this decline. On October 9, the analysis firm HC Wainwright revised its earnings forecasts for fiscal 2025 downwards, changing the loss per share estimate from -$1.44 to -$2.48, a deterioration of over 70%. Particularly, the announcement on October 9 of the acquisition of American competitor Akero Therapeutics by Danish giant Novo Nordisk for an amount that could reach $5.2 billion might weigh on investor sentiment. This transaction strengthens the competition in the highly contested MASH sector, where Inventiva is developing its drug candidate lanifibranor. With a beta coefficient of 0.51, the stock shows a sensitivity half that of market movements, partly explaining its evolution decoupled from the Parisian index.

Technical Analysis and Future Outlook

Technically, several indicators signal persistent selling pressure. The Relative Strength Index, at 37, is approaching the traditionally oversold zone around 30, without entering it, indicating weakening but not yet excessive bearishness. The MACD, a momentum indicator, confirms this negative orientation with a directive line at -0.01, significantly below its signal line positioned at 0.11, while the negative histogram at -0.11 reflects an ongoing bearish dynamic. The Chaikin Money Flow, negative at -0.17, reinforces this reading by pointing to a predominance of selling flows over buying flows. The stock is now trading below its 50-day moving average, set at €4.24, materializing a short-term bearish trend. However, it still remains above its 200-day moving average, located at €3.10, thus preserving a fundamental bullish orientation. The technical support threshold at €3.99, which corresponded to the previous day's price, was breached during this session and could now act as resistance in the event of a rebound. The monthly volatility, measured at 18.17%, reflects the amplitude of recent fluctuations in the stock, in a context where investors seem to be reevaluating the sector's prospects following last week's announcements.